Co-crystal & Salt Screening
Selecting the optimal solid form of an API during early drug development can mitigate the risk of failure later in development.
This can be achieved through polymorph, salt, and cocrystal screening.
1
Co-crystal Screening
Choose suitable co-formers to design experiments; Co-crystal form identification and characterization; Thermodynamic phase relationship study; Stability and solubility evaluation; Co-crystal form recommendation.
2
Salt Screening
Design various salt-forming experiments according to the physicochemical properties of compound; Salt form identification and characterization; Thermodynamic phase relationship study; Stability and solubility evaluation; Salt type selection and salt form recommendation.
3
Polymorph Screening
Design various crystallization conditions according to the physicochemical properties of the compound; Crystal form identification and characterization; Thermodynamic phase relationship stud; Stability and solubility evaluation; Optimal solid form recommendation.
Capabilities - Solid Form Screening
Drug Discovery
Focused Form Screening
-
Physiochemical Property
-
Developability assessment
Pre-clinical
Polymorph/Salt/Co-crystal Screening
-
Thermodynamic phase relationship
-
Stability and solubility evaluation
-
Optimal form recommendation
Clinical
Extensive Form Screening
-
Form evaluation
-
Patenting of polymorph/salt